CA2785851A1 - Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction - Google Patents

Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction Download PDF

Info

Publication number
CA2785851A1
CA2785851A1 CA2785851A CA2785851A CA2785851A1 CA 2785851 A1 CA2785851 A1 CA 2785851A1 CA 2785851 A CA2785851 A CA 2785851A CA 2785851 A CA2785851 A CA 2785851A CA 2785851 A1 CA2785851 A1 CA 2785851A1
Authority
CA
Canada
Prior art keywords
corneal endothelial
endothelial cells
pyrrolo
benzamide
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2785851A
Other languages
English (en)
French (fr)
Inventor
Hiroaki Takahashi
Yuji Sakamoto
Tetsuo Kida
Takeshi Tarui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharmaceutical Co Ltd
Publication of CA2785851A1 publication Critical patent/CA2785851A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2785851A 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction Abandoned CA2785851A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009-299180 2009-12-29
JP2009299180 2009-12-29
JPPCT/JP2010/071424 2010-11-24
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (1)

Publication Number Publication Date
CA2785851A1 true CA2785851A1 (en) 2011-07-07

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785851A Abandoned CA2785851A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Country Status (10)

Country Link
US (1) US20120288482A1 (https=)
EP (1) EP2519237A1 (https=)
JP (2) JP5750444B2 (https=)
KR (1) KR20120099147A (https=)
CN (1) CN102770136A (https=)
BR (1) BR112012016128A8 (https=)
CA (1) CA2785851A1 (https=)
MX (1) MX2012007671A (https=)
RU (1) RU2563141C2 (https=)
WO (2) WO2011080984A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2788472T (lt) * 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
WO2015097920A1 (ja) * 2013-12-27 2015-07-02 京都府公立大学法人 角膜内皮細胞の細胞治療併用剤
JP6598381B2 (ja) * 2014-09-24 2019-10-30 興和株式会社 角膜厚調節剤
CN121891508A (zh) * 2014-10-31 2026-04-21 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
PL3416658T3 (pl) * 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CN100411686C (zh) 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
JPWO2006057270A1 (ja) * 2004-11-26 2008-06-05 旭化成ファーマ株式会社 含窒素３環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
US20090062295A1 (en) * 2005-03-10 2009-03-05 Mitsubishi Pharma Corporation Pharmaceutical Products
WO2007083685A1 (ja) * 2006-01-19 2007-07-26 Senju Pharmaceutical Co., Ltd. 生体内で細胞増殖可能な角膜内皮製剤
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
KR20210070407A (ko) 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
KR20120099147A (ko) 2012-09-06
MX2012007671A (es) 2012-08-23
JP2013515676A (ja) 2013-05-09
RU2012132443A (ru) 2014-02-10
RU2563141C2 (ru) 2015-09-20
WO2011081221A1 (en) 2011-07-07
JP5750444B2 (ja) 2015-07-22
BR112012016128A8 (pt) 2017-12-05
JP2015155460A (ja) 2015-08-27
CN102770136A (zh) 2012-11-07
WO2011080984A1 (en) 2011-07-07
BR112012016128A2 (pt) 2016-05-31
EP2519237A1 (en) 2012-11-07
US20120288482A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
CA2785851A1 (en) Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
JP2014527407A5 (https=)
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
GB2438544A (en) Liquid formulations for treatment of diseases or conditions
WO2011139684A3 (en) Nicotine-containing pharmaceutical compositions
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
WO2009023877A3 (en) Formulations for treatment of ocular diseases or conditions
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2010053655A3 (en) Therapeutic methods with withaferin a and analogs
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2009033782A3 (en) Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
WO2020263980A8 (en) IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2013515676A5 (https=)
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
RU2014132553A (ru) Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2009033660A3 (en) Use of octreotide as a therapeutic agent
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150806

FZDE Discontinued

Effective date: 20180516